Hjem › Lungekreft › California › Orange
Kliniske studier for Lungekreft i Orange, CA
14 studier for Lungekreft søker deltakere på steder i og rundt Orange (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RekruttererFase 3
- University of California, Irvine Health, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekruttererFase 3
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekruttererFase 2/3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- UC IRVINE Health, Orange
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Rekrutterer
- Primary Care & Internal Medicine Services, Orange
- UCI Chao Family Comprehensive Cancer Center, Orange
- UCI Health SeniorHealth Center -Pavillion 4, Orange
- og 1 flere
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekruttererFase 3
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekruttererFase 3
- Providence St. Joseph Hospital, Orange
Patient-Derived Xenografts to Reduce Cancer Health Disparities
RekruttererObservasjonsstudie
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RekruttererFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekruttererFase 1/2
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
RekruttererFase 2
- University of California, Irvine Medical Center, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RekruttererFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Orange
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
Rekrutterer
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
Lungekreft-studier i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Arlington, VA41 studier
- Washington, DC41 studier
- Chicago, IL41 studier
- Baltimore, MD40 studier
- Nashville, TN40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i Orange
- Ikke-småcellet lungekreft25 studier
- Metastatisk kreft20 studier
- Kolorektal kreft16 studier
- Eggstokkreft16 studier
- Pankreaskreft15 studier
- Melanom14 studier
- Leverkreft (hepatocellulært karcinom)14 studier
- Brystkreft14 studier
- Prostatakreft14 studier
- Mavekreft13 studier
- Kreft (alle typer)13 studier
- Akut myelogen leukemi13 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.